This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Amodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2006 by University of Ghana Medical School.
Recruitment status was:  Active, not recruiting
University of Copenhagen
Information provided by:
University of Ghana Medical School Identifier:
First received: November 13, 2006
Last updated: November 30, 2006
Last verified: November 2006
Artemisinin combination therapies (ACT) are currently recommended for malaria treatment. Artemether-lumefantrine(A-L) and Artesunate+amodiaquine (A+A) have been the most commonly adopted of the recommended ACT regimens. In Ghana, A+A is the current first-line antimalarial treatment in Ghana, but there has been 1 efficacy report of this regimen in Ghana till date. Moreover, the safety of repeated treatments with ACT has been little studied. This study aims to evaluate the efficacy of A+A vs. A-L, as well as the safety of repeated treatments of these regimens in a longitudinal trial in which recruited children will be followed up for 1 year.

Condition Intervention Phase
Uncomplicated Malaria Drug: amodiaquine+artesunate/artemether-lumefantrine Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by University of Ghana Medical School:

Study Start Date: October 2004
Estimated Study Completion Date: December 2006

Ages Eligible for Study:   6 Months to 14 Years   (Child)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • microscopically confirmed acute uncomplicated falciparum malaria;
  • temperature at screening 37.50C or more or history of fever 24 preceding enrollment;
  • willingness to comply with follow up schedule;
  • written informed consent by accompanying parent or guardian

Exclusion Criteria:

  • features of severe malaria or danger signs of malaria
  • known intolerance or allergy to any of the study medications
  • known treatment with any of the study medications in the month preceding enrollment
  • serious underlying disease that may mask outcome assessment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00406146

Korle Bu Teaching Hospital
Accra, Ghana
Sponsors and Collaborators
University of Ghana Medical School
University of Copenhagen
Principal Investigator: George O. Adjei, MD Dept. of Child Health, Korle Bu Teaching Hospital, Accra, Ghana
Principal Investigator: Bamenla Q. Goka, MBchB Dept of Child Health, Korle Bu Teaching Hospital, Accra, Ghana
Principal Investigator: Jorgen A.L. Kurtzhals, MD, Ph.D Dept. of Clinical Microbiology, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00406146     History of Changes
Other Study ID Numbers: 91199 / 104. DAN.8-864
Study First Received: November 13, 2006
Last Updated: November 30, 2006

Additional relevant MeSH terms:
Protozoan Infections
Parasitic Diseases
Artemether-lumefantrine combination
Amodiaquine, artesunate drug combination
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Antifungal Agents
Antiplatyhelmintic Agents
Anthelmintics processed this record on September 21, 2017